Stockscreener 앱 받기
2.16
6.49%
-0.15
시간 외 거래:
2.12
-0.04
-1.85%
전일 마감가:
$2.31
열려 있는:
$2.375
하루 거래량:
2.02M
Relative Volume:
0.91
시가총액:
$94.15M
수익:
$16.77M
순이익/손실:
$-11.87M
주가수익비율:
-4.555
EPS:
-0.4742
순현금흐름:
$-5.90M
1주 성능:
+24.86%
1개월 성능:
+131.69%
6개월 성능:
+274.67%
1년 성능:
+158.99%
1일 변동 폭
$2.00
$2.41
1주일 범위
$1.61
$2.41
52주 변동 폭
$0.30
$2.41
Immunoprecise Antibodies Ltd Stock (IPA) Company Profile
IPA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IPA
Immunoprecise Antibodies Ltd
|
2.16 | 83.29M | 16.77M | -11.87M | -5.90M | -0.4742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunoprecise Antibodies Ltd Stock (IPA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-02 | 개시 | H.C. Wainwright | Buy |
| 2021-10-25 | 개시 | The Benchmark Company | Buy |
Immunoprecise Antibodies Ltd 주식(IPA)의 최신 뉴스
Is ImmunoPrecise Antibodies Ltd. a good long term investmentMarket-leading profit generation - PrintWeekIndia
IPA’s Stock Market Labyrinth: Navigating 2025’s Gains and Declines - investchronicle.com
ImmunoPrecise Unveils Breakthrough in Predicting Drug Antibody Risks - TipRanks
ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic - Yahoo Finance
What drives ImmunoPrecise Antibodies Ltd. stock priceDynamic portfolio growth - Autocar Professional
What analysts say about ImmunoPrecise Antibodies Ltd. stockFree Predictions - jammulinksnews.com
ImmunoPrecise Antibodies Ltd. Stock Analysis and ForecastRapid portfolio appreciation - jammulinksnews.com
ImmunoPrecise Strengthens Advisory Board with AI Expert Jeff Fried - The Globe and Mail
ImmunoPrecise Antibodies (OTCMKTS:IPATF) Stock Price Down 0.6% – What’s Next? - Defense World
ImmunoPrecise Antibodies appoints data expert Jeff Fried to advisory board - Investing.com Australia
ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board - Yahoo Finance
Is ImmunoPrecise Antibodies Ltd. stock a good hedge against inflationFree Investment Portfolio Suggestions - beatles.ru
why immunoprecise antibodies ltd. stock attracts strong analyst attentionMarket Beating Strategy - Newser
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025 - 01net
ImmunoPrecise Antibodies to Announce Q4 and FY 2025 Results - TipRanks
Why ImmunoPrecise Antibodies Ltd. stock attracts strong analyst attentionElite Stock Shortlist - Newser
How ImmunoPrecise Antibodies Ltd. stock performs during market volatilityShort Squeeze Radar - Newser
Tech Momentum Surges as IPA, HIT, SNYR, PNPN.V, KAPA and Others Drive Investor Awareness – More Stocks Inside - FinancialContent
What makes ImmunoPrecise Antibodies Ltd. stock price move sharplyFree Risk Assessment Services - Newser
ImmunoPrecise Regains Nasdaq Compliance, Strengthening Market Position - The Globe and Mail
ImmunoPrecise regains Nasdaq compliance as share price stabilizes By Investing.com - Investing.com South Africa
ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement - 01net
ImmunoPrecise Antibodies Ltd Inc. (IPA) Price Performance: The Role of Share Buybacks and Stock Splits - investchronicle.com
ImmunoPrecise regains Nasdaq compliance as share price stabilizes - Investing.com
ImmunoPrecise Antibodies Appoints Jon Lieber to Board of Directors - citybiz
ImmunoPrecise Antibodies Strengthens Board with Industry Veteran Jon Lieber - TipRanks
ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors - New Castle News
ImmunoPrecise Antibodies’ LENSai Platform Achieves Breakthrough in Epitope Mapping Accuracy - Insider Monkey
ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data - 01net
ImmunoPrecise Antibodies Skyrockets: AI-Powered Drug Discovery Takes Center Stage - RagingBull
ImmunoPrecise’s LENSai Platform Achieves Breakthrough in Antibody Binding Prediction - TipRanks
Immunoprecise Antibodies Ltd (IPA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.97%
0.22%
자본화:
|
볼륨(24시간):